Is Taxus Ready To Face REALITY? Cordis Primes The Pump On Late Loss

Johnson & Johnson/Cordis' evaluation of Cypher drug-eluting stent superiority over Boston Scientific's Taxus will extend to "all significant patient segments" within J&J's REALITY head-to-head trial commencing this summer, Cordis noted June 5